Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
By D. Miles, A. Chan, L. Dirix, J. Cortés, X. Pivot, P. Tomczak, T. Delozier, J. Sohn, L. Provencher, F. Puglisi and 6 more. Journal of Clinical Oncology, 2010
910 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/5522f22705b23c73ea1f02d66bcd979bff5ee04b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- Ten years of anti-vascular endothelial growth factor therapy (2016, result): “…combination with paclitaxel in February 2008 for the treatment of metastatic HER2-negative breast cancer, and, although response rates and PFS were improved compared with paclitaxel alone 94 , subsequent studies, using first-or second-line bevacizumab, reported smaller improvements in PFS 95–97 .”
- Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence (2014, background): “…adjuvant traztuzumab for breast cancer (Romond et al, 2005)) and RCTs evaluating drugs with marginal effects and substantial toxicity (e.g., bevacizumab for advanced breast cancer (Miles et al, 2010; Robert et al, 2011), and aflibercept for advanced colorectal cancer (Van Cutsem et al, 2012)).”
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy (2012, background): “This finding may have implications beyond active immunotherapy in breast cancer, where the use of low doses of bevacizumab with chemotherapy ultimately may contribute to improvements of overall survival (33, 34).”